Program Book

Recommendations

Info

Results. The study included 37 women and 13 men with a median age of 68.5 years (range: 44 to 86 years). There were 44 whites, 5 hispanics, and 1 Asian. Tumor location was in the upper eyelid in 28 patients, in the lower eyelid in 15 patients, and involved both upper and lower eyelids in 7 patients. AJCC 7th edition TNM designations were: TxN0M0,7 patients (pts); T1N0M0,4 pts.;T2aN0M0,12 pts.;T2bN0M0,11 pts.; T2bN1M0, 2 pts; T2bN1M1,1 patient (pt.);T3aN0M0,2 pt.; T3aN1M0,5 pts.; T3bN0M0, 1 pt; T3bN1M0,1 pt; T3bN0M1,2 pt.; T4N0M0,1 pt.; and T4N0M1,1pt. Regional lymph node metastasis was seen in 9 patients (18%). The TNM designation for these 9 patients at last contact were: T2bN1M0 (2 pts), T2bN1M1 (1pt.), T3aN1M0 (5 pts.), T3bN1M0 (1 pt). Presence of lymph node metastasis was significantly associated with T-stage at presentation (P = 0.0079). No tumors less than T2b had nodal metastasis. No tumors less than 9 mm in greatest dimension had nodal metastasis. Distant metastasis was documentable in 4 patients and death from disease occurred in 5 patients (10%). The TNM designations for these 5 patients were: T2bN1M1 (1pt.), T3bN0M1 (2pts.), T4N0M0 (1 pt), and T4N0M1 (1pt). No tumors less than 12 mm in greatest dimension were associated with distant metastasis or death. Disease-specific survival (DSS) was significantly associated with T-stage of the primary tumor (P = 0.0009). DSS was poorer among patients who presented with a tumor > T3a using the 2-category t-stage (P = 0.035). Conclusions. The 7th edition AJCC criteria for eyelid carcinomas correlate with outcomes for sebaceous carcinoma of eyelid. Tumor size correlates with regional lymph node metastasis with tumors >10 mm in greatest dimension being at risk. Sebaceous carcinomas > T3a are associated with poorer survival. Financial disclosure. None 2244 EC5 LYMPHOMA OF THE EYELIDS – A NATION-BASED STUDY Steffen Heegaard1,3, Peter K. Rasmussen 1, Elisabeth Ralfkiaer2, Lene D. Sjö2 and Jan U. Prause1 (sthe@sund.ku.dk) 1. Department of Neuroscience and Pharmacology, Eye Pathology Institute, University of Copenhagen, Denmark 2. Department of Pathology, Copenhagen University Hospital, Denmark 3. Department of Ophthalmology, University of Copenhagen, Glostrup Hospital, Denmark Purpose. To characterize the clinicopathological features of lymphoma of the eyelids Methods. All cases of eyelid lymphoma between 1980 and 2008 were retrieved from the Danish Registry of Pathology. Histological specimens were re-evaluated using a panel of monoclonal antibodies. Clinical files from all patients with confirmed lymphoma were collected. Results. Twenty-five patients with lymphoma of the eyelids were identified. Thirteen of the patients were males and the median age was 66 years (range 31 to 83 years). The distribution of lymphoma subtypes were: extranodal marginal zone lymphoma (EMZL) 44% (11), mantle cell lymphoma (MCL) 20% (5), follicular lymphoma (FL) 12% (3), diffuse large B-cell lymphoma (DLBCL) 8% (2), peripheral T-cell lymphoma, unspecified (PTCL, NOS) 8% (2), chronic lymphocytic leukemia/ small lymphatic lymphoma (CLL/SLL) 4% (1) and anaplastic large T-cell lymphoma (T-ALCL) 4% (1). Fourteen patients (56%) presented with Stage I/II lymphoma. Two patients (8%) had Stage III lymphoma and nine patients (36%) presented with Stage IV lymphoma. The 5-year overall survival rate (OS) was 42%. The patients with lowgrade lymphoma subtypes (EMZL; FL; PTCL, NOS; CLL/SLL) had a EYELID, CONJUNTIVA & ORBIT Abstracts 68 significantly better 3-year OS rate (77%) than patients with high-grade lymphoma (MCL; DLBCL; T-ALCL) (3-year OS rate, 21%). Conclusions. Lymphoma of the eyelids is relatively rare and is mainly prevalent in elderly patients. Most patients had unilateral involvement. The occurrence of MCL was relatively high compared to the distribution of lymphoma subtypes of the orbit. The prognosis for the whole population was relatively poor, however, patients with low-grade lymphoma had a significantly better survival. Financial disclosure. None 143 EC6 DIAGNOSIS AND FOLLOW-UP OF OCULAR SURFACE SQUAMOUS NEOPLASIA BASED ON NON-INVASIVE IN VIVO BIOPSY USING CONFOCAL MICROSCOPY J. Oscar Croxatto, MD, Carolina Gentile, MD (juan.croxatto@gmail.com) Oncology Unit, Hospital Italiano de Buenos Aires, Fundación Oftalmológica Argentina J. Malbran and Laboratorios Pörtner, Buenos Aires, Argentina. Purpose. To analyze the tissue findings, diagnosis and follow-up of corneal and conjunctival epithelial neoplasia in a large series of patients examined with in vivo confocal microscopy. Methods. Fifty-five patients with a presumed diagnosis of corneal and conjunctival epithelial neoplasia underwent examination with in vivo confocal microscopy (CCFM) (Rostock corneal module/HRTII, Heildelberg). The CCFM findings were compared with histology and cytology in those cases which underwent surgical excision or ocular surface impression cytology. The main outcome measures were CCFM findings, diagnosis, resolution after therapy, and histopathologic and cytologic findings. Results. The CCFM diagnoses were cornea and conjunctival intraepithelial neoplasia (38 cases), early invasive epithelial neoplasia (4 cases), intraepithelial neoplasia and pterygium (3 cases), stem cell deficiency (3 cases), UV-related keratosis (4 cases), pterygium without epithelial atypia (2 cases), and squamous cell carcinoma (1 case). CCFM findings showed a precise correlation with histopathological and cytological specimens. The post-medication examination procedure could confirm resolution ad integrum in patients treated with mitomycin C, and periodic evaluation until complete resolution in those patients receiving interferon alfa2-b. Subclinical recurrences were identified in 3 cases. Conclusions. CCFM provides an excellent non-invasive in vivo image method to confirm the diagnosis of cornea and conjunctival neoplasia, to detect early invasion, to guide medical treatment in patients undergoing topical therapy, and to differentiate limbal and corneal simulating diseases. Financial disclosure. None 1459 EC7 OCULAR SURFACE SQUAMOUS NEOPLASIA IN A PATIENT WITH HIV INFECTION: REGRESSION AFTER RESTARTING ANTIRETROVIRAL THERAPY WITH DEVELOPMENT OF SPECIFIC T-CELLS M. Marinkovic, A. Rengifo Coolman, M.J.P. Schoenmaekers-Welters, S. van der Burg, M.J. Jager, G.P.M. Luyten (m.marinkovic@yahoo.com) Dept. of Ophthalmology and Dept. of Oncology, Leiden University Medical Centre, Leiden , The Netherlands
Purpose. Ocular surface squamous neoplasia (OSSN) refers to precancerous and cancerous lesions of the conjunctiva ranging form conjuctival intraepithelial neoplasia (CIN) to an invasive tumor with destruction of the orbital tissues. OSSN used to affect elderly men, yet this pattern has changed. In Africa the incidence is rising in younger persons, mostly women around 35 years of age. This increasing prevalence is probably due to HIV infection and HPV co-infections. Methods. Clinical and immunological analysis including testing of specific T cell interferon-gamma immune responses, and tissue HPV type analysis. Results. A 50 year-old female presented with complaints of chronical blepharoconjunctivitis which had existed for a couple of years. She was HIV positive and used antiretroviral medication infrequently. An eye examination revealed extensive leukoplakia of the palpebral and bulbar conjunctiva and cornea in the left eye. As a biopsy revealed squamous cell carcinoma with infiltration of the tarsal and bulbar conjunctiva of the left eye, exenteration of the left orbit was planned. When admitted to the hospital after a patients delay of a couple of months, the lesion of the conjunctival lesion had almost disappeared. The patient mentioned that she had restarted to take her HAART medication conscientiously. Earlier biopsies showed the presence of HPV 16, and at the time of tumor regression, anti-HPV16 T-cell responses were found to be present. Conclusions. Meticulous use of antiretroviral medication may cause regression of OSSN. It is unclear whether the medication targets the underlying HIV or HPV infection, or indirectly led to healing by allowing the recurrence of an anti-HPV16 T cell immune response. The lack of compliance in the use of therapy could be added to the list of risk factors for OSSN. Further research is needed to confirm this suggestion. Financial disclosure. None 12 EC8 RUTHENIUM PLAQUE THERAPY IN THE MANAGEMENT OF CONJUNCTIVAL SQUAMOUS CELL CARCINOMA INVADING THE EYE Priscilla L. Ballalai, Virginia L. Torres, Roberto Segretto (pbbordon@ terra.com.br) Ocular Oncology Section - Federal University of Sao Paulo Radiotherapy - Federal University of Sao Paulo Purpose. To describe the outcome of patients with conjunctival squamous cell carcinoma invading the eye treated with Ruthenium (Ru106) plaque therapy. Methods. Retrospective, non-comparative review of charts of patients referred to the University and private office with conjunctival squamous cell carcinoma (SCC) invading the eye, from January 2001 to July 2011. Patients with focal invasions at the cornea, sclera or iris and ciliary body were included. Patients with orbital infiltrations or extensive intraocular infiltrations were excluded. All patients were submitted to Ru 106 plaque therapy, and the treatment dose was 50 Gy. The duration of the treatment was calculated according to the UBM measurements with a 1 mm safety margin. The patients were followed with a complete ophthalmological examination and systemic evaluation after the treatment. Results. Twenty patients with conjunctival SCC invading the eye were seen by the authors from January 2001 to July 2011. Six of them were eligible for salvage therapy with ruthenium plaque therapy. One patient was HIV positive. The mean age was 58 yo (range 29-82 yo), 4 were females and 2 males. The mean follow up of was 31,5 mo (range 6 -108 EYELID, CONJUNTIVA & ORBIT Abstracts 69 mo). All of them had been treated previously with surgery or surgery and topical chemotherapy (Mitomycin C and/or Interferon). The mean number of surgeries was 2,1 (range 1-4). The pathological evaluation confirmed the diagnosis of SCC in all patients. Infiltration of the corneal stroma was observed in 3 patients, deep scleral infiltration in 4 patients and iris and ciliary body infiltration in 1 patient. All patients had regression of the tumor after the treatment without recurrence in the treatment site or elsewhere. None of them presented distant metastasis. The only complication observed with this treatment was cataract, in 3 patients. Conclusions. Ruthenium plaque therapy is safe and effective in the management of eyes with focal infiltrations by conjunctival squamous cell carcinoma. Financial disclosure. None 1059 EC9 INVASIVE SQUAMOUS CELL CARCINOMA OF THE CONJUNCTIVA TREATED BY PROTONS W. Sauerwein1, J. Herault2, P. Chauvel2, H. Westekemper3, R. Darawsha3, B. Zimmermann1, C. Maschi4, A. Wittig5, L. Brualla1, J.-P. Caujolle4 (w.sauerwein@uni-due.de) 1. University Duisburg- Essen, University Hospital Essen, Department of Radiation Oncology, Essen, Germany 2. Cyclotron Biomédicale, Centre Antoine-Lacassagne, Nice, France 3. University Duisburg- Essen, University Hospital Essen, Department of Ophthalmology, Essen, Germany 4. Service d’Ophtalmologie, CHU Saint Roch, Nice, France 5. Klinikum der Philipps-Universität Marburg, Department of Radiation Oncology Marburg, Germany Purpose. Squamous cell carcinoma (SCC) of the conjunctiva is an extremely rare disease. The disease is suspected to be associated with atrophic dermatitis and HIV in young women. After local excision the tumor often recurs instead of adjuvant therapies such as cryocoagulation, local chemotherapy or radiotherapy. Conventional external beam radiotherapy with electrons or photons is not conducive as the dose needed to control the tumor will destroy the eye. A sufficient dose can only be delivered by brachytherapy if the tumor is localized on the eyeball and if the target volume can be covered by a radioactive plaque. Therefore, exenteration is often the only curative approach. Protons might offer an alternative as they can be collimated and modulated to cover a complex area of the conjunctiva including fornix and tarsus while protecting the inner part of the eye and radiosensitive structures in the neighbourhood. Methods. The irradiation technique was initially developed to treat melanoma of the conjunctiva. The target volume to be considered is large and individually shaped. It includes often more than half of the total surface of the conjunctiva, with the goal to avoid further relapses at the margin of the treated volume. Because of the large volume, the number of fractions has been extended as compared to conventional proton therapy of uveal melanoma. The dose applied is given in 6 fractions of 5.2 Gy (36 Gy RBE) followed by a boost of 2 fractions of 7 Gy (16 Gy RBE). The technical principles of the treatment are as follows: - the clips are inserted on the eye for localization of the target volume and positioning. A bolus is set-up on the lid to give a homogeneous flat entrance for the proton beam collimated to the size of the tumor, - the beam passes through a semi-spherical acrylic glass compensator to adapt the range of the proton beam to the shape the inner sclera and let the protons irradiate the thickness of sclera and conjunctiva. The compensator is individually customized from an acrylic glass block by a computerized milling machine. The resulting dose distribution is
Page 1 and 2:
XV th NH City Hotel and Tower Boliv
Page 3 and 4:
List of Congress Meetings of the In
Page 5:
Table of Contents Welcome address K
Page 8 and 9:
Keynote Lectures Lymphoma of the oc
Page 10 and 11:
The venue for the Biannual Meeting
Page 12 and 13:
Buenos Aires Downtown MAP 12 Venue
Page 15 and 16:
MORNING 8.30-10.10 Papers (Moderato
Page 17 and 18: 50 RES 26 USING THE GLYCOLYTIC INHI
Page 19 and 20: 2226 RES 4 NOTCH SIGNALING PROMOTES
Page 21 and 22: a reduction in the number of living
Page 23 and 24: array further detected copy number
Page 25 and 26: 615 RES 21 TRB2 AND SKP2 IN THE RET
Page 27: following treatment with 2-fluorode
Page 30 and 31: 1909 Rb14 RESULTS OF PATIENTS WITH
Page 32 and 33: Posters Retinoblastoma 2006 RBp100
Page 34 and 35: 120 RBp135 MANAGEMENT OF AN ECTOPIC
Page 36 and 37: After treatment, 10 patients lived
Page 38 and 39: Methods. Six cycles of carboplatin
Page 40 and 41: 1940 RB15 PROTON THERAPY FOR RECURR
Page 42 and 43: 4. Fluoroscopy for cannula placemen
Page 44 and 45: Methods. A retrospective chart revi
Page 46 and 47: Ruth A. Kleinerman1, Chu-ling Yu1,
Page 48 and 49: 2006 RBp100 RETINOBLASTOMA ASSESSME
Page 50 and 51: months. Mean delay between beginnin
Page 52 and 53: not associated with severity of RB.
Page 54 and 55: Conclusions. During a ten-year peri
Page 56 and 57: 30 RBp127 TREATMENT MODULATION IN R
Page 58 and 59: (follow-up 5 years). Two years afte
Page 61 and 62: 8.30-9.00 Poster presentations ECOp
Page 63 and 64: Uvea (Moderators: B. Damato, M. Sag
Page 65 and 66: Morning 8.30-9.00 Poster presentati
Page 67: 1621 EC1 EVALUATION OF THE “HEDGE
Page 71 and 72: (cargusale@yahoo.com) Oncology Serv
Page 73 and 74: of the tissues most commonly affect
Page 75 and 76: 2128 RF1 RETINOBLASTOMA David H. Ab
Page 77 and 78: Ocular Oncology Service, St Barthol
Page 79 and 80: Arturo Irarrazaval, Pablo Cazon, Os
Page 81 and 82: A CASE OF TEARING AND SWELLING OF T
Page 83 and 84: 1849 ECp101 FIVE CASES OF CARCINOMA
Page 85 and 86: patients. The isolated involvement
Page 87 and 88: exudative fluid from the hemangioma
Page 89: maximum of 7 rituximab injections.
Page 92 and 93: 153 UM14 PHENO-GENOTYPIC IDENTIFICA
Page 94 and 95: 8.30-9.00 Poster presentations UMp1
Page 96 and 97: 2253 UM1 PRELIMINARY STUDY OF VASCU
Page 98 and 99: Purpose. To determine the presence
Page 100 and 101: gene expression profile of melanocy
Page 102 and 103: the rarity of UM, timely completion
Page 104 and 105: C. Metz, T. Gkika, W. Sauerwein, N.
Page 106 and 107: Patients in the triamcinolone group
Page 108 and 109: 1350 Ump101 INDUCED EXPRESSION OF P
Page 110 and 111: Purpose. To report the Results of R
Page 112 and 113: 1547 Ump113 LONG-TERM OBSERVATIONS
Page 114 and 115: 2038 Ump119 VALUE OF DOPPLER ANALYS
Page 116: Methods. A total of 4070 patients w
Page 119:
First authors Naseripour, Masood No
show all

Program Book

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?